Delivering the Added Dimension in Drug Discovery Services
Read the latest press releases from Jubilant Biosys in the developments within the broad spectrum of CRO chemistry services, as well as our recent collaborative programs with leading global healthcare companies.
Our flexible approach helps clients understand more about our role in improving the quality of our discovery informatics, structural biology, medicinal chemistry, drug discovery services, in-vitro models and translational sciences.
13th May 2020
“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.
28th Nov 2019
Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started the design and construction of a brand new state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site.
8th May 2019
Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years.
28th March 2019
Jubilant Biosys announced today that it has added advanced Pioneer FE system to its platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio represents the next generation SPR instrumentation for label-free characterization of biomolecules.
13th February 2019
Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders.
29th November 2017
Jubilant Biosys announced today that they successfully achieved an early stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders.
19th September 2016
Jubilant Biosys Ltd announced two new leadership appointments. Mr. Steven Hutchins has been appointed as President and Dr. Takeshi Yura has been appointed as Vice President of Medicinal Chemistry.
26th May 2016
Jubilant today announced the signing of an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for…
7th Jan 2016
Collaboration aimed at discovery and development of small molecule inhibitors through to Phase I proof of mechanism in metabolic disorders therapeutic area.